Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Herrero A
  • Pinto A
  • Colón-Bolea P
  • Casar B
  • Jones M
  • Agudo-Ibáñez L
  • Vidal R
  • Tenbaum SP
  • Nuciforo P
  • Valdizán EM
  • Horvath Z
  • Orfi L
  • Bony E
  • Keri G
  • Rivas G
  • Pazos A
  • Gozalbes R
  • Palmer HG
  • Hurlstone A

Grupos

Abstract

Nearly 50% of human malignancies exhibit unregulated RAS-ERK signaling; inhibiting it is a valid strategy for antineoplastic intervention. Upon activation, ERK dimerize, which is essential for ERK extranuclear, but not for nuclear, signaling. Here, we describe a small molecule inhibitor for ERK dimerization that, without affecting ERK phosphorylation, forestalls tumorigenesis driven by RAS-ERK pathway oncogenes. This compound is unaffected by resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two understudied concepts in cancer therapy: (1) the blockade of sub-localization-specific sub-signals, rather than total signals, as a means of impeding oncogenic RAS-ERK signaling and (2) targeting regulatory protein-protein interactions, rather than catalytic activities, as an approach for producing effective antitumor agents.

Datos de la publicación

ISSN/ISSNe:
1535-6108, 1878-3686

Cancer Cell  CELL PRESS

Tipo:
Article
Páginas:
170-182
Factor de Impacto:
13,740 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 97

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • MUTATIONS CONFER RESISTANCE; MAP KINASE ERK2; ACQUIRED-RESISTANCE; CANCER-THERAPY; COLON-CANCER; BRAF; DIMERS; CELLS; MEK; ACTIVATION

Campos de estudio

Proyectos asociados

INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP

Investigador Principal: CARMEN RIBES KONINCKX

643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015

UNA APROXIMACIÓN ÓMICA AL DIAGNÓSTICO DE LA TUBERCULOSIS

PCIN-2013-041 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2015

HERRAMIENTAS DE RMN PARA EL DESARROLLO DE UNA PLATAFORMA PARA LA IDENTIFICACIÓN DE DIANAS, LA EVALUACIÓN DE FÁRMACOS Y LA PERSONALIZACIÓN DE TRATAMIENTOS BASADA EN APROXIMACIONES METABOLÓMICAS

Investigador Principal: ANTONIO PINEDA LUCENA

SAF2014-53977-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2015

Cita

Compartir